Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q3 FY26 Earnings Presentation
18 slides from Gland Pharma's earnings presentation, Jan 28, 2026
Slide 1: Investor Presentation Q3 & 9M FY26
GLAND PHARMA Investor Presentation Q3 & 9M FY26 28 January 2026
Slide 2: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 3: Financial Highlights
in Financial Highlights
Slide 4: Consolidated P&L Highlights
Consolidated P&L Highlights ₹ Mn Particulars Q3 FY26 Q3 FY25 YoY Q2 FY26 QoQ 9M FY26 9M FY25 YoY Revenue from operations 16,954 13,841 22% 14,869 14% 46,879 41,916 12% Other Income 632 585 8% 842 -25% 2,049 1,696 21% Total Income 17,585 14,426 22% 15,710 12% 48,927 43,612 12% Gross Profit(1) 11,187
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (₹ Mn) (₹ Mn / %) 46,879 30,363 41,916 25,892 65% 62% 16,954 11,187 13,841 14,869 9,213 9,331 67% 63% 66% Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Adj. EBITDA (
Slide 6: Base Business (Gland) P&L Highlights
Base Business (Gland) P&L Highlights ₹ Mn Particulars Q3 FY26 Q3 FY25 YoY Q2 FY26 QoQ 9M FY26 9M FY25 YoY Revenue from operations 11,790 10,123 16% 10,767 10% 32,965 30,917 7% Other Income 631 555 14% 861 -27% 2,048 1,643 25% Total Income 12,421 10,678 16% 11,628 7% 35,013 32,559 8% Gross Profit(1)
Slide 7: Base Business (Gland) Financial Highlights
Base Business (Gland) Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (₹ Mn) (₹ Mn / %) 32,965 30,917 19,862 17,663 57% 60% 10,123 10,767 11,790 6,357 6,571 7,147 63% 61% 61% Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Adj.
Slide 8: Group Financial Highlights (1/2)
Group Financial Highlights (1/2) Net Worth (1) ROCE (2) / RONW (3) (₹ Mn) (%) RoCE RoNW 87,238 91,507 98,789 11% 15.00% 11% 9% 10.00% 9% 9% 8% 5.00% 0.00% FY24 FY25 9M FY26 FY24 FY25 9M FY26 Capital Expenditure Asset Turnover Ratio (4)(5) (₹ Mn) (x) 3,975 3,938 3,566 1.5 1.4 1.5 0.6 0.5 0.5 Total as
Slide 9: Group Financial Highlights (2/2)
Group Financial Highlights (2/2) Cash and Bank Balances / Net Cash (1) Cash Flow from Operations (₹ Mn) Total Cash (₹ Mn) Net Cash 26,565 6,228 5,889 6,269 25,562 22,870 23,191 18,394 15,197 FY24 FY25* 9M FY26* 9M FY24 9M FY25 9M FY26 . * Excluding non-callable deposits of INR 3,960 million. Net Wor
Slide 10: Business Update
in Business Update
Slide 11: Base Business (Gland) Updates
Base Business (Gland) Updates • R&D Expenses: Total R&D expenses were ₹650 million in Q3 FY26, representing 5.4% of revenue versus ₹437 million, representing 4.3% of revenues, in Q3 FY25. The increase in R&D is on account of complex product development and number of filings. • New Launches: The comp
Slide 12: Cenexi Updates
Cenexi Updates Q3 FY26 Q3 FY25 Q2 FY26 9M FY26 9M FY25 Particulars YoY QoQ YoY € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. Revenue from operations 50 5,164 41 3,717 39% 40 4,102 26% 138 13,913 121 10,999 26% Gross Margin 39 4,040 32 2,856 41% 27 2,760 46% 104 10,501 91 8,229 28% % ma
Slide 13: Geographical Revenue
SS Geographical — Revenue |
Slide 14: US Market
US Market ₹ Mn Group Revenue Contribution Gland Cenexi 19% YoY 9% YoY 16% YoY 6% YoY 150% YoY 126% YoY 22,052 23,466 941 22,469 24,407 395 417 7,293 8,279 8,685 7,135 8,005 8,290 274 158 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9
Slide 15: Europe Market
Europe Market ₹ Mn Group Revenue Contribution Gland Cenexi 54% YoY 33% YoY 42% YoY 23% YoY 56% YoY 35% YoY 1,421 8,800 10,221 1,155 6,517 7,672 593 3,478 2,847 4,071 419 2,227 2,658 2,646 189 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M F
Slide 16: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, Australia and New Zealand) ₹ Mn Group Revenue Contribution Gland Cenexi -1% YoY 18% YoY -15% YoY 10% YoY 37% YoY 34% YoY 1,680 647 1,420 1,033 937 483 459 488 454 338 288 215 166 273 121 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25 9M FY26 Q3 FY
Slide 17: Rest of the World
Rest of the World ₹ Mn Group Revenue Contribution Gland Cenexi 4% YoY 2% YoY 12% YoY 4% YoY -7% YoY -2% YoY Own Products TT & CMO 4,810 5,044 8,392 8,568 3,582 3,524 1,023 704 2,881 2,590 3,000 1,669 1,635 1,876 1,212 1,124 142 3,786 4,340 955 225 326 1,444 1,493 1,550 Q3 FY25 Q2 FY26 Q3 FY26 9M FY2
Slide 18: Thank You
GLAND PHARMA Thank You Corporate Office Investor Relations: Gland Pharma Limited Sampath Kumar Pallerlamudi Plot No. 11 & 84, TSIIC Phase: IV Company Secretary & Compliance Officer Pashamylaram (V), Patancheru (M), Sangareddy District Shriniwas P. Dange Hyderabad 502307, Telangana, India Investor Re